A major blow has been dealt to pharmaceutical giant Bayer in a high-stakes court battle over prostate cancer treatment. A US judge has rejected Bayer's bid to block rival Johnson & Johnson from making claims about the effectiveness of its prostate cancer drug, Zytiga. The ruling is a significant victory for Johnson & Johnson, which has been seeking to expand its market share in the lucrative prostate cancer treatment space. The decision could have far-reaching implications for the pharmaceutical industry, with Bayer facing potential losses and Johnson & Johnson poised to gain a competitive edge in the market.
US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims Reuters
